Lexeo Therapeutics (LXEO)

• Market cap: $489M
• 1 day: 4.53%
• 5 days: 9.3%
• 1 month: 7.97%
• 3 months: -12.99%
• 6 months: -26.01%
• Year to date: -35.17%
• 1 year: 91.69%
• 5 years: -38.01%
• 10 years: -38.01%
• Sector: Healthcare
• Industry: Biotechnology

About: Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Employees: 59